Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B4MK
|
|||
| Former ID |
DPR000181
|
|||
| Drug Name |
ISIS-STAT3
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Company |
ISIS Pharm
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01563302) Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.